Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1893 1
1901 2
1902 1
1910 1
1917 1
1926 1
1927 1
1928 1
1929 1
1930 2
1931 4
1934 1
1936 2
1939 2
1940 2
1941 2
1950 1
1951 1
1953 1
1959 3
1960 1
1961 1
1962 1
1965 6
1966 1
1967 2
1968 4
1969 4
1971 3
1972 4
1973 2
1974 2
1975 4
1976 4
1977 8
1978 8
1979 8
1980 4
1981 3
1982 5
1983 7
1984 2
1985 12
1986 8
1987 9
1988 12
1989 8
1990 10
1991 15
1992 17
1993 19
1994 19
1995 22
1996 14
1997 17
1998 15
1999 8
2000 10
2001 8
2002 13
2003 14
2004 15
2005 14
2006 9
2007 14
2008 15
2009 12
2010 18
2011 34
2012 36
2013 35
2014 32
2015 39
2016 29
2017 53
2018 37
2019 53
2020 51
2021 48
2022 41
2023 43
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

915 results

Results by year

Filters applied: . Clear all
Page 1
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC. Lancet JE, et al. Among authors: banerjee k. J Clin Oncol. 2018 Sep 10;36(26):2684-2692. doi: 10.1200/JCO.2017.77.6112. Epub 2018 Jul 19. J Clin Oncol. 2018. PMID: 30024784 Free PMC article. Clinical Trial.
Nonviral delivery of self-amplifying RNA vaccines.
Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, Cu Y, Beard CW, Brito LA, Krucker T, O'Hagan DT, Singh M, Mason PW, Valiante NM, Dormitzer PR, Barnett SW, Rappuoli R, Ulmer JB, Mandl CW. Geall AJ, et al. Among authors: banerjee k. Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14604-9. doi: 10.1073/pnas.1209367109. Epub 2012 Aug 20. Proc Natl Acad Sci U S A. 2012. PMID: 22908294 Free PMC article.
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T. Kelley RK, et al. Among authors: banerjee k. Lancet Oncol. 2022 Aug;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4. Lancet Oncol. 2022. PMID: 35798016 Free article. Clinical Trial.
SATB2 preserves colon stem cell identity and mediates ileum-colon conversion via enhancer remodeling.
Gu W, Wang H, Huang X, Kraiczy J, Singh PNP, Ng C, Dagdeviren S, Houghton S, Pellon-Cardenas O, Lan Y, Nie Y, Zhang J, Banerjee KK, Onufer EJ, Warner BW, Spence J, Scherl E, Rafii S, Lee RT, Verzi MP, Redmond D, Longman R, Helin K, Shivdasani RA, Zhou Q. Gu W, et al. Among authors: banerjee kk. Cell Stem Cell. 2022 Jan 6;29(1):101-115.e10. doi: 10.1016/j.stem.2021.09.004. Epub 2021 Sep 27. Cell Stem Cell. 2022. PMID: 34582804 Free PMC article.
The future transistors.
Cao W, Bu H, Vinet M, Cao M, Takagi S, Hwang S, Ghani T, Banerjee K. Cao W, et al. Among authors: banerjee k. Nature. 2023 Aug;620(7974):501-515. doi: 10.1038/s41586-023-06145-x. Epub 2023 Aug 16. Nature. 2023. PMID: 37587295 Review.
H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models.
Haase S, Banerjee K, Mujeeb AA, Hartlage CS, Núñez FM, Núñez FJ, Alghamri MS, Kadiyala P, Carney S, Barissi MN, Taher AW, Brumley EK, Thompson S, Dreyer JT, Alindogan CT, Garcia-Fabiani MB, Comba A, Venneti S, Ravikumar V, Koschmann C, Carcaboso ÁM, Vinci M, Rao A, Yu JS, Lowenstein PR, Castro MG. Haase S, et al. Among authors: banerjee k. J Clin Invest. 2022 Nov 15;132(22):e154229. doi: 10.1172/JCI154229. J Clin Invest. 2022. PMID: 36125896 Free PMC article.
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
Brose MS, Robinson BG, Sherman SI, Jarzab B, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Sen S, Oliver JW, Banerjee K, Keam B, Capdevila J. Brose MS, et al. Among authors: banerjee k. Cancer. 2022 Dec 15;128(24):4203-4212. doi: 10.1002/cncr.34493. Epub 2022 Oct 19. Cancer. 2022. PMID: 36259380 Free PMC article. Clinical Trial.
Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy.
Alghamri MS, Banerjee K, Mujeeb AA, Mauser A, Taher A, Thalla R, McClellan BL, Varela ML, Stamatovic SM, Martinez-Revollar G, Andjelkovic AV, Gregory JV, Kadiyala P, Calinescu A, Jiménez JA, Apfelbaum AA, Lawlor ER, Carney S, Comba A, Faisal SM, Barissi M, Edwards MB, Appelman H, Sun Y, Gan J, Ackermann R, Schwendeman A, Candolfi M, Olin MR, Lahann J, Lowenstein PR, Castro MG. Alghamri MS, et al. Among authors: banerjee k. ACS Nano. 2022 Jun 28;16(6):8729-8750. doi: 10.1021/acsnano.1c07492. Epub 2022 May 26. ACS Nano. 2022. PMID: 35616289 Free PMC article.
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Hernando J, Faoro L, Banerjee K, Oliver JW, Keam B, Capdevila J. Brose MS, et al. Among authors: banerjee k. Lancet Oncol. 2021 Aug;22(8):1126-1138. doi: 10.1016/S1470-2045(21)00332-6. Epub 2021 Jul 5. Lancet Oncol. 2021. PMID: 34237250 Clinical Trial.
VEGF-C-expressing TAMs rewire the metastatic fate of breast cancer cells.
Banerjee K, Kerzel T, Bekkhus T, de Souza Ferreira S, Wallmann T, Wallerius M, Landwehr LS, Agardy DA, Schauer N, Malmerfeldt A, Bergh J, Bartish M, Hartman J, Östman A, Squadrito ML, Rolny C. Banerjee K, et al. Cell Rep. 2023 Dec 26;42(12):113507. doi: 10.1016/j.celrep.2023.113507. Epub 2023 Dec 1. Cell Rep. 2023. PMID: 38041815 Free article.
915 results